DNA Methylation of the PITX2 Gene Promoter Region is a Strong Independent Prognostic Marker of Biochemical Recurrence in Patients With Prostate Cancer After Radical Prostatectomy

Journal of Urology

Volumn 181, Issue 4, 2009, Pages 1678-1685

  Weiss, Gunter ^a   Cottrell, Susan ^c   Distler, Jürgen ^a   Schatz, Philipp ^a   Kristiansen, Glen ^a   Ittmann, Michael ^e   Haefliger, Carolina ^a   Lesche, Ralf ^a   Hartmann, Arndt ^b   Corman, John ^d   Wheeler, Thomas ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c EPIGENOMICS AG   (Germany)

^d VIRGINIA MASON MEDICAL CENTER   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

DNA methylation; prognosis; prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR PITX2; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; DNA EXTRACTION; DNA METHYLATION; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR BIOPSY; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSTATECTOMY; PROSTATIC NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 62349136443     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.11.120     Document Type: Article

References (20)

1. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591
2. Roehl K.A., Han M., Ramos C.G., Antenor J.A., and Catalona W.J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172 (2004) 910
3. Shariat S.F., Karakiewicz P.I., Margulis V., and Kattan M.W. Inventory of prostate cancer predictive tools. Curr Opin Urol 18 (2008) 279
4. Perry A.S., Foley R., Woodson K., and Lawler M. The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr Relat Cancer 13 (2006) 357
5. Laird P.W. The power and the promise of DNA methylation markers. Nat Rev Cancer 3 (2003) 253
6. Cottrell S., Jung K., Kristiansen G., Eltze E., Semjonow A., Ittmann M., et al. Discovery and validation of three novel DNA methylation markers of prostate cancer prognosis. J Urol 177 (2007) 1753
7. Maier S., Nimmrich I., Koenig T., Eppenberger-Castori S., Bohlmann I., Paradiso A., et al. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients: technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology Group. Eur J Cancer 43 (2007) 1679
8. Nimmrich I., Sieuwerts A.M., Meijer-van Gelder M.E., Schwope I., Bolt-de Vries J., Harbeck N., et al. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res Treat 111 (2008) 429
9. Tetzner R., Dietrich D., and Distler J. Control of carry-over contamination for PCR-based DNA methylation quantification using bisulfite treated DNA. Nucleic Acids Res 35 (2007) e4
10. Martens J.W., Nimmrich I., Koenig T., Look M.P., Harbeck N., Model F., et al. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 65 (2005) 4101
11. Grossfeld G.D., Chang J.J., Broering J.M., Miller D.P., Yu J., Flanders S.C., et al. Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database. J Urol 163 (2000) 1171
12. Stamey T.A., McNeal J.E., Yemoto C.M., Sigal B.M., and Johnstone I.M. Biological determinants of cancer progression in men with prostate cancer. JAMA 281 (1999) 1395
13. Cox D.R., and Oakes D. Analysis of Survival Data (1984), Chapman & Hall, Boca Raton, Florida
14. Therneau T.M., and Grambsch P.M. Modeling Survival Data (2000), Springer, New York
15. Semina E.V., Reiter R., Leysens N.J., Alward W.L., Small K.W., Datson N.A., et al. Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndrome. Nat Genet 14 (1996) 392
16. Kioussi C., Briata P., Baek S.H., Rose D.W., Hamblet N.S., Herman T., et al. Identification of a Wnt/Dvl/beta-Catenin -> Pitx2 pathway mediating cell-type-specific proliferation during development. Cell 111 (2002) 673
17. Toyota M., Kopecky K.J., Toyota M.O., Jair K.W., Willman C.L., and Issa J.P. Methylation profiling in acute myeloid leukemia. Blood 97 (2001) 2823
18. Cox C.J., Espinoza H.M., McWilliams B., Chappell K., Morton L., Hjalt T.A., et al. Differential regulation of gene expression by PITX2 isoforms. J Biol Chem 277 (2002) 25001
19. Harbeck N., Nimmrich I., Hartmann A., Ross J.S., Cufer T., Grützmann R., et al. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol 26 (2008) 5036
20. Lopez-Otin C., and Diamandis E.F. Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev 19 (1998) 365